Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy

NCT ID: NCT05554393Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-17

Summary

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.

Detailed description

PRIMARY OBJECTIVE: I. To compare the rates of undetectable measurable residual disease (MRD) in patients who achieve a complete remission (CR) after induction therapy with 7 +3 (cytarabine + daunorubicin hydrochloride \[daunorubicin\]) versus (vs.) azacitidine + venetoclax vs. 7+3 + venetoclax. SECONDARY OBJECTIVES: I. To estimate the frequency and severity of toxicities with each of the regimens. II. To estimate complete remission (CR) rates (with and without MRD), complete remission with incomplete count recovery (CRi) (with and without MRD) rates, event-free survival (EFS), relapse-free survival (RFS), and overall survival (OS) with each of the regimens. TERTIARY OBJECTIVES: I. To evaluate response to therapy received according to genomic findings. II. To evaluate MRD kinetics by following patients with detectable MRD through Tier 2 and beyond. III. To evaluate longer term outcomes by treatment arm, genomics, MRD outcome, and other features as patients receive additional myeloMATCH therapies to generate testable hypotheses for more precise patient selection for these therapies. OUTLINE: Patients are randomized to 1 of 3 arms. ARM I: Patients receive daunorubicin intravenously (IV) on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax orally (PO) once per day (QD) on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. ARM II: Patients receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. ARM III: Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. After completion of study treatment, patients are followed up at 4 weeks, every 3 months for 1 year every 6 months for the second year and yearly thereafter.

Arms & interventions

  • DrugAzacitidine

    Given IV or SC

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • DrugCytarabine

    Given IV

  • DrugDaunorubicin Hydrochloride

    Given IV

  • DrugVenetoclax

    Given PO

Outcome measures

Primary

  • Measurable residual disease (MRD) undetectable complete remission (CR)

    Will assess after one induction cycle with or without the addition of venetoclax or two cycles of venetoclax and azacitidine. MRD by flow cytometry will be considered undetectable if ≤ 10\^-3. The MRD negative CR will be assessed using European LeukemiaNet (ELN) 2017 criteria \[Döhner 2017\]. The analysis population for the primary outcome will be all randomized patients with the intent to treat population. The MRD undetectable CR rate will be the number of patients with MRD undetectable CR divided by the total number of patients. The differences of MRD undetectable CR rates between the experimental groups and the control group will be estimated and the corresponding one-sided 80% confidence limit will be calculated using Normal distribution approximation. MRD non-evaluable patients will be considered as MRD positive.

    Time frame: Up to 2 cycles (56 days)

Secondary

  • Frequency and severity of toxicities with each of the regimens

    Time frame: Up to 10 years

  • CR rates

    Time frame: Up to 2 cycles (56 days)

  • Complete remission with incomplete count recovery (CRi)

    Time frame: Up to 2 cycles (56 days)

  • Event-free survival

    Time frame: From the date of randomization to the first: date of primary refractory disease; date of progressive disease; date off protocol therapy without CR or CRi; date of relapse from CR or CRi, or death from any cause, assessed up to 10 years

  • Relapse-free survival

    Time frame: From the time of CR or CRi, until the relapse from CR or CRi, or death from any cause, assessed up to 10 years

  • Overall survival

    Time frame: From randomization to the time of death from any cause, assessed up to 10 years

  • Responses to therapy received relative to genomic findings

    Time frame: Up to 10 years

Eligibility criteria

Sex: AllAge: 18 Years to 59 YearsHealthy volunteers: No
Inclusion Criteria: * Patient must have enrolled onto MYELOMATCH and must have been given a treatment assignment to MyeloMATCH to MM1YA-CTG01 based on the presence of an actionable mutation as defined in MYELOMATCH * Participants must have been registered to master screening and re-assessment protocol (myeloMATCH MSRP) prior to consenting to this study. Participants must have been assigned to this clinical trial, via MATCHBox Protocol Assignment Team, prior to registration to this study. Participants must have agreed to have specimens submitted for translational medicine (MRD) and must be offered the opportunity to submit biosamples for banking for future research as per the myeloMATCH MSRP * Note: Pre-enrollment/diagnosis labs must have already been performed under the MSRP * Previously untreated, de novo acute myeloid leukemia (AML) defined by \> 20% myeloblasts in the peripheral blood or bone marrow (refer to the 2016 updated World Health Organization \[WHO\] classification of myeloid neoplasms and acute leukemia) excluding all the following categories of AML: * Favorable cytogenetics: (t(8;21)q22;q22.1); RUNX1-RUNX1T1, inversion 16(p13.1;q22), t(16;16)(p13.1;q22); CBFB-MYH11 * CEBPA biallelic mutations * NPM1 mutation * AML with PML-RARalpha * AML with any adverse cytogenetics, TP53 mutation, RUNX1 mutation, ASXL1, 11q23/KMT2 rearrangements * AML with FLT3-ITD or FLT3-TKD mutations * Therapy related AML, or AML following a diagnosis of myelodysplasia or myeloproliferative neoplasm Participants with central nervous system (CNS) disease are eligible for this trial and will be treated according to institutional guidelines with intrathecal chemotherapy for this aspect of their disease * Age 18-59 years at time of induction therapy * Eastern Cooperative Oncology Group (ECOG) performance status =\< 3 * Total bilirubin =\< 2 x institutional upper limit of normal (ULN) (must be done within 7 days of enrollment) * Aspartate aminotransferase (AST) (serum glutamate pyruvate transaminase \[SGPT\]) +/or alanine aminotransferase (ALT) (serum glutamic-oxaloacetic transaminase \[SGOT\]) =\< 3 × institutional ULN (must be done within 7 days of enrollment) * Cardiac ejection fraction \>= 50% (echocardiography or multigated acquisition scan \[MUGA\]) (if clinically indicated must be done within 14 days of enrollment) * Calculated creatinine clearance \>= 30 mL/min/ 1.73m\^2; Clearance to be calculated using Cockcroft formula (must be done within 7 days of enrollment) * White blood cells (WBC) must be \< 25 x 10\^9/L. Hydroxyurea and leukapheresis are permitted to control the WBC prior to enrollment and initiation of protocol-defined therapy but must be stopped at least 24 hours prior to the initiation of protocol therapy. 1 dose of cytarabine at 1 mg/m\^2 for urgent cytoreduction is also permitted * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Males and females of reproductive potential must have agreed to use a highly effective contraceptive method while on treatment and for 6 months after stopping study drug. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. Women of childbearing potential will have a pregnancy test to determine eligibility as part of the pre-study evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected. Patient will be considered eligible if an ultrasound is negative for pregnancy * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate * Patients must be accessible for treatment, response assessment and follow up. Patients enrolled on this trial must be treated and followed at the participating centre. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up. Patients must agree to return to their primary care facility for any adverse events which may occur through the course of the trial * In accordance with Canadian Cancer Trials Group (CCTG) policy, protocol treatment is to begin within 7 working days of patient enrollment * Participants receiving strong or moderate CYP3A inhibitors must agree to discontinue use at least 48 hours prior to start of study treatment if assigned to arm 1 or 2 * Patients with known human immunodeficiency virus (HIV) infection who are on effective anti-retroviral therapy and have undetectable viral load within 6 months of enrollment are eligible for this trial * Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load within 28 days of enrollment. Patients need to be on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection who have been treated and cured are eligible. Patients who with active HCV infection who are currently being treated must have an undetectable HCV viral load within 28 days of enrollment to be eligible Exclusion Criteria: * Prior therapy for AML except for hydroxyurea and leukapheresis to control blood counts. The use of all-trans retinoic acid (ATRA) is permitted until a diagnosis of acute promyelocytic leukemia, if suspected, is ruled out * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cytarabine, daunorubicin, azacitidine, venetoclax * Pregnant women are excluded from this study because venetoclax, cytarabine and azacitidine have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, cytarabine and azacitidine breastfeeding should be discontinued if the mother is treated with venetoclax, cytarabine and azacitidine. These potential risks may also apply to other agents used in this study * Patients with isolated myeloid sarcoma are not eligible * Any other serious intercurrent illness, life threatening condition, organ system dysfunction, or medical condition judged by the local investigator to compromise the subject's safety (for example): * Active, uncontrolled bacterial, fungal, or viral infection

Study locations (167)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

Recruiting
Site Public Contact · Contact
gingerreeves@uabmc.edu
Razan Mohty · Principal Investigator

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Sharad Khurana · Principal Investigator

University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Sharad Khurana · Principal Investigator

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205

Recruiting
Site Public Contact · Contact
501-686-8274
Ankur Varma · Principal Investigator

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, 94704

Suspended

Cedars-Sinai Medical Center

Los Angeles, California, 90048

Recruiting
Site Public Contact · Contact
310-423-2133Cancer.trial.info@cshs.org
Noah M. Merin · Principal Investigator

UCSF Medical Center-Parnassus

San Francisco, California, 94143

Recruiting
Site Public Contact · Contact
877-827-3222
Timothy Ferng · Principal Investigator

Miami Cancer Institute

Miami, Florida, 33176

Recruiting
Site Public Contact · Contact
786-596-2000
Firas El Chaer · Principal Investigator

Memorial Hospital West

Pembroke Pines, Florida, 33028

Recruiting
Site Public Contact · Contact
954-265-4325
Yehuda E. Deutsch · Principal Investigator

Phoebe Putney Memorial Hospital

Albany, Georgia, 31701

Recruiting
Site Public Contact · Contact
229-312-0405ga_cares@augusta.edu
Vamsi Kota · Principal Investigator

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Tareq Al baghdadi · Principal Investigator

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Centralia Oncology Clinic

Centralia, Illinois, 62801

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
312-695-1301cancer@northwestern.edu
Shira N. Dinner · Principal Investigator

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Crossroads Cancer Center

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201

Recruiting
Site Public Contact · Contact
847-570-2109
Amy Y. Wang · Principal Investigator

NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026

Recruiting
Site Public Contact · Contact
847-570-2109
Amy Y. Wang · Principal Investigator

NorthShore University HealthSystem-Highland Park Hospital

Highland Park, Illinois, 60035

Recruiting
Site Public Contact · Contact
847-570-2109
Amy Y. Wang · Principal Investigator

Loyola University Medical Center

Maywood, Illinois, 60153

Recruiting
Site Public Contact · Contact
708-226-4357
Stephanie B. Tsai · Principal Investigator

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

UChicago Medicine Northwest Indiana

Crown Point, Indiana, 46307

Recruiting
Site Public Contact · Contact
855-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242

Recruiting
Site Public Contact · Contact
800-237-1225
Prajwal Dhakal · Principal Investigator

University of Kansas Clinical Research Center

Fairway, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Heather J. Male · Principal Investigator

University of Kansas Cancer Center

Kansas City, Kansas, 66160

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Heather J. Male · Principal Investigator

University of Kansas Hospital-Indian Creek Campus

Overland Park, Kansas, 66211

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Heather J. Male · Principal Investigator

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Heather J. Male · Principal Investigator

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Recruiting
Site Public Contact · Contact
859-257-3379
Ayman Qasrawi · Principal Investigator

The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, 40202

Recruiting
Site Public Contact · Contact
502-562-3429
Mohamed M. Hegazi · Principal Investigator

UofL Health Medical Center Northeast

Louisville, Kentucky, 40245

Recruiting
Site Public Contact · Contact
502-852-2755ctoinfo@louisville.edu
Mohamed M. Hegazi · Principal Investigator

LSU Health Baton Rouge-North Clinic

Baton Rouge, Louisiana, 70805

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Harry G. Sequeira Gross · Principal Investigator

Our Lady of the Lake Physician Group

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Harry G. Sequeira Gross · Principal Investigator

Our Lady of The Lake

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659
Harry G. Sequeira Gross · Principal Investigator

MaineHealth Maine Medical Center - Portland

Portland, Maine, 04102

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

MaineHealth Maine Medical Center- Scarborough

Scarborough, Maine, 04074

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

MaineHealth Cancer Care and IV Therapy - South Portland

South Portland, Maine, 04106

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

Walter Reed National Military Medical Center

Bethesda, Maryland, 20889-5600

Recruiting
Site Public Contact · Contact
301-319-2100
Ryan Jones · Principal Investigator

Tufts Medical Center

Boston, Massachusetts, 02111

Recruiting
Site Public Contact · Contact
617-636-5000ContactUsCancerCenter@TuftsMedicalCenter.org
Andreas K. Klein · Principal Investigator

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Recruiting
Site Public Contact · Contact
877-442-3324
Eric S. Winer · Principal Investigator

Lahey Hospital and Medical Center

Burlington, Massachusetts, 01805

Recruiting
Site Public Contact · Contact
781-744-3421lhmc-cancer-clinical-trials@lahey.org
Hossein Sadrzadeh · Principal Investigator

Lahey Clinic Peabody

Peabody, Massachusetts, 01960

Recruiting
Site Public Contact · Contact
781-744-3421lhmc-cancer-clinical-trials@lahey.org
Hossein Sadrzadeh · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, Michigan, 48038

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Henry Ford Hospital

Detroit, Michigan, 48202

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Cancer Hematology Centers - Flint

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Genesee Hematology Oncology PC

Flint, Michigan, 48503

Suspended

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Hurley Medical Center

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Allegiance Health

Jackson, Michigan, 49201

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Medical Center-Columbus

Novi, Michigan, 48377

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Mercy Hospital

Coon Rapids, Minnesota, 55433

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Cancer Center

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Fairview Southdale Hospital

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746

Recruiting
Site Public Contact · Contact
218-786-3308
Bret E. Friday · Principal Investigator

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Regions Hospital

Saint Paul, Minnesota, 55101

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

United Hospital

Saint Paul, Minnesota, 55102

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health Sandstone

Sandstone, Minnesota, 55072

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Golden Triangle

Columbus, Mississippi, 39705

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Cancer Center-Grenada

Grenada, Mississippi, 38901

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Union County

New Albany, Mississippi, 38652

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Oxford

Oxford, Mississippi, 38655

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Desoto

Southhaven, Mississippi, 38671

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Community Hospital of Anaconda

Anaconda, Montana, 59711

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Nebraska Medicine-Bellevue

Bellevue, Nebraska, 68123

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Michael Haddadin · Principal Investigator

Nebraska Medicine-Village Pointe

Omaha, Nebraska, 68118

Recruiting
Site Public Contact · Contact
402-559-5600
Michael Haddadin · Principal Investigator

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Michael Haddadin · Principal Investigator

OptumCare Cancer Care at Charleston

Las Vegas, Nevada, 89102

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

OptumCare Cancer Care at Fort Apache

Las Vegas, Nevada, 89183

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756

Recruiting
Site Public Contact · Contact
800-639-6918cancer.research.nurse@dartmouth.edu
Raphael A. Lizcano · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Saint Barnabas Medical Center

Livingston, New Jersey, 07039

Recruiting
Site Public Contact · Contact
973-322-2934joanne.loeb@rwjbh.org
Neil D. Palmisiano · Principal Investigator

Monmouth Medical Center

Long Branch, New Jersey, 07740

Recruiting
Site Public Contact · Contact
732-923-6564mary.danish@rwjbh.org
Neil D. Palmisiano · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

Recruiting
Site Public Contact · Contact
732-235-7356
Neil D. Palmisiano · Principal Investigator

The Valley Hospital - Luckow Pavilion

Paramus, New Jersey, 07652

Recruiting
Site Public Contact · Contact
201-634-5792clinicaltrialsresearch@valleyhealth.com
Jason Suh · Principal Investigator

Valley Health System Ridgewood Campus

Ridgewood, New Jersey, 07450

Recruiting
Site Public Contact · Contact
201-634-5792clinicaltrialsresearch@valleyhealth.com
Jason Suh · Principal Investigator

Community Medical Center

Toms River, New Jersey, 08755

Recruiting
Site Public Contact · Contact
732-557-8294Lennette.Gonzales@rwjbh.org
Neil D. Palmisiano · Principal Investigator

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

Recruiting
Site Public Contact · Contact
505-925-0348HSC-ClinicalTrialInfo@salud.unm.edu
Charles Foucar · Principal Investigator

Roswell Park Cancer Institute

Buffalo, New York, 14263

Recruiting
Site Public Contact · Contact
800-767-9355askroswell@roswellpark.org
Eunice S. Wang · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Mount Sinai Hospital

New York, New York, 10029

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Douglas A. Tremblay · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

University of Rochester

Rochester, New York, 14642

Recruiting
Site Public Contact · Contact
585-275-5830
Paul M. Barr · Principal Investigator

Stony Brook University Medical Center

Stony Brook, New York, 11794

Recruiting
Site Public Contact · Contact
800-862-2215
Suhu Liu · Principal Investigator

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Ioannis Mantzaris · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Xin Wang · Principal Investigator

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

Recruiting
Site Public Contact · Contact
800-804-9376
Thomas G. Knight · Principal Investigator

Novant Health Presbyterian Medical Center

Charlotte, North Carolina, 28204

Recruiting
Site Public Contact · Contact
980-201-6360kashah@novanthealth.org
Patricia L. Kropf · Principal Investigator

Duke University Medical Center

Durham, North Carolina, 27710

Recruiting
Site Public Contact · Contact
888-275-3853
Harry P. Erba · Principal Investigator

East Carolina University

Greenville, North Carolina, 27834

Recruiting
Site Public Contact · Contact
252-744-1015eubankss@ecu.edu
Darla K. Liles · Principal Investigator

Novant Health Forsyth Medical Center

Winston-Salem, North Carolina, 27103

Recruiting
Site Public Contact · Contact
336-718-8335pjordan@novanthealth.org
James P. Dugan · Principal Investigator

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157

Recruiting
Site Public Contact · Contact
336-713-6771
Bayard L. Powell · Principal Investigator

Case Western Reserve University

Cleveland, Ohio, 44106

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Ali W. Bseiso · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Manu Pandey · Principal Investigator

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Tareq Al baghdadi · Principal Investigator

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Charles W. Drescher · Principal Investigator

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Charles W. Drescher · Principal Investigator

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Tareq Al baghdadi · Principal Investigator

Geisinger Medical Center

Danville, Pennsylvania, 17822

Recruiting
Site Public Contact · Contact
570-271-5251HemonCCTrials@geisinger.edu
Joseph J. Vadakara · Principal Investigator

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033-0850

Recruiting
Site Public Contact · Contact
717-531-3779CTO@hmc.psu.edu
Joseph Cioccio · Principal Investigator

Lewistown Hospital

Lewistown, Pennsylvania, 17044

Recruiting
Site Public Contact · Contact
717-242-7703HemonCCTrials@geisinger.edu
Joseph J. Vadakara · Principal Investigator

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-647-8073
Annie P. Im · Principal Investigator

Reading Hospital

West Reading, Pennsylvania, 19611

Recruiting
Site Public Contact · Contact
610-988-9323
Terrence P. Cescon · Principal Investigator

Geisinger Wyoming Valley/Henry Cancer Center

Wilkes-Barre, Pennsylvania, 18711

Recruiting
Site Public Contact · Contact
570-271-5251HemonCCTrials@geisinger.edu
Joseph J. Vadakara · Principal Investigator

Prisma Health Cancer Institute - Spartanburg

Boiling Springs, South Carolina, 29316

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Easley

Easley, South Carolina, 29640

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Butternut

Greenville, South Carolina, 29605

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Faris

Greenville, South Carolina, 29605

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Eastside

Greenville, South Carolina, 29615

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Greer

Greer, South Carolina, 29650

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Seneca

Seneca, South Carolina, 29672

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Collierville

Collierville, Tennessee, 38017

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Memphis

Memphis, Tennessee, 38120

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030

Recruiting
Site Public Contact · Contact
713-798-1354burton@bcm.edu
Tareq Abuasab · Principal Investigator

Ben Taub General Hospital

Houston, Texas, 77030

Recruiting
Site Public Contact · Contact
713-873-2000
Tareq Abuasab · Principal Investigator

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Paul J. Shami · Principal Investigator

University of Vermont Medical Center

Burlington, Vermont, 05401

Recruiting
Site Public Contact · Contact
802-656-4101rpo@uvm.edu
Diego A. Adrianzen Herrera · Principal Investigator

University of Vermont and State Agricultural College

Burlington, Vermont, 05405

Recruiting
Site Public Contact · Contact
802-656-8990rpo@uvm.edu
Diego A. Adrianzen Herrera · Principal Investigator

University of Virginia Cancer Center

Charlottesville, Virginia, 22908

Recruiting
Site Public Contact · Contact
434-243-6303uvacancertrials@hscmail.mcc.virginia.edu
Daniel R. Reed · Principal Investigator

Inova Schar Cancer Institute

Fairfax, Virginia, 22031

Recruiting
Site Public Contact · Contact
703-720-5210Stephanie.VanBebber@inova.org
Danielle A. Shafer · Principal Investigator

Inova Fairfax Hospital

Falls Church, Virginia, 22042

Recruiting
Site Public Contact · Contact
703-208-6650Stephanie.VanBebber@inova.org
Danielle A. Shafer · Principal Investigator

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

Duluth Clinic Ashland

Ashland, Wisconsin, 54806

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601

Recruiting
Site Public Contact · Contact
608-775-2385cancerctr@gundersenhealth.org
Kurt Oettel · Principal Investigator

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting
Site Public Contact · Contact
414-805-3666
Karen-Sue B. Carlson · Principal Investigator

Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Adedayo A. Onitilo · Principal Investigator

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Adedayo A. Onitilo · Principal Investigator